Journal of Medicinal Chemistry · 2021 · 64 citations · 36 references
Life SciencesMedicinal ChemistryOncologyDrug DiscoveryMolecular OncologyProtein-protein InteractionsEnzyme InhibitionLigand BindingProtein-ligand DockingProtein-ligand InteractionsRas Family OncogenesTargeted Cancer TherapyEgfr InhibitionIn Vivo Efficacy TestingKras InhibitorsKras-targeted TherapyOncogenic Driver MutationsOncology-related Protein-protein Interaction TargetsProtein Binding In OncologyProtein-protein Interaction Inhibitor Discovery
KRAS, the most common oncogenic driver in human cancers, is controlled and signals primarily through protein–protein interactions (PPIs). The interaction between KRAS and SOS1, crucial for the activation of KRAS, is a typical, challenging PPI with a large contact surface area and high affinity. Here, we report that the addition of only one atom placed between Y884SOS1 and A73KRAS is sufficient to convert SOS1 activators into SOS1 inhibitors. We also disclose the discovery of BI-3406. Combination with the upstream EGFR inhibitor afatinib shows in vivo efficacy against KRASG13D mutant colorectal tumor cells, demonstrating the utility of BI-3406 to probe SOS1 biology. These findings challenge the dogma that large molecules are required to disrupt challenging PPIs. Instead, a “foot in the door” approach, whereby single atoms or small functional groups placed between key PPI interactions, can lead to potent inhibitors even for challenging PPIs such as SOS1-KRAS.
36
Ethan Cerami, Jianjiong Gao, Uğur Doğrusöz et al. · Cancer Discovery · 2012 · 18.4K citations · Full text
Medicine, Bioinformatics, Oncology +15
Inference of Macromolecular Assemblies from Crystalline State
Evgeny Krissinel, Kim Henrick · Journal of Molecular Biology · 2007 · 10.4K citations · Full text
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations
Medicine, Oncology, Pharmacology +14